A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this pivotal, phase 3, randomized, multicenter study is to compare VB-111 plus
bevacizumab to bevacizumab in adult patients with recurrent Glioblastoma.
Phase:
Phase 3
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics